| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Molecular Diagnostic Techniques | 7 | 2025 | 29 | 1.290 |
Why?
|
| Coronavirus | 5 | 2020 | 12 | 1.250 |
Why?
|
| Severe Acute Respiratory Syndrome | 4 | 2020 | 24 | 1.220 |
Why?
|
| Multiplex Polymerase Chain Reaction | 5 | 2024 | 14 | 1.170 |
Why?
|
| Coronavirus Infections | 10 | 2020 | 191 | 1.050 |
Why?
|
| Pandemics | 11 | 2022 | 614 | 0.990 |
Why?
|
| RNA, Viral | 16 | 2023 | 259 | 0.960 |
Why?
|
| Pneumonia, Viral | 8 | 2020 | 204 | 0.900 |
Why?
|
| Clinical Laboratory Techniques | 3 | 2020 | 42 | 0.880 |
Why?
|
| Sensitivity and Specificity | 14 | 2025 | 1093 | 0.860 |
Why?
|
| Betacoronavirus | 8 | 2020 | 166 | 0.750 |
Why?
|
| Genome, Viral | 2 | 2020 | 120 | 0.750 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2021 | 42 | 0.710 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 8 | 2022 | 527 | 0.710 |
Why?
|
| Real-Time Polymerase Chain Reaction | 6 | 2025 | 191 | 0.700 |
Why?
|
| Germany | 10 | 2024 | 52 | 0.690 |
Why?
|
| Meningitis | 1 | 2020 | 18 | 0.670 |
Why?
|
| Encephalitis | 1 | 2020 | 33 | 0.660 |
Why?
|
| Staining and Labeling | 1 | 2020 | 123 | 0.640 |
Why?
|
| High-Throughput Screening Assays | 6 | 2025 | 74 | 0.570 |
Why?
|
| Humans | 68 | 2025 | 59282 | 0.560 |
Why?
|
| Monkeypox virus | 4 | 2024 | 8 | 0.530 |
Why?
|
| Chiroptera | 3 | 2010 | 10 | 0.490 |
Why?
|
| Viral Envelope Proteins | 7 | 2022 | 100 | 0.480 |
Why?
|
| Virus Internalization | 5 | 2022 | 81 | 0.450 |
Why?
|
| Viral Proteins | 3 | 2022 | 252 | 0.410 |
Why?
|
| Autopsy | 6 | 2022 | 53 | 0.400 |
Why?
|
| Membrane Glycoproteins | 7 | 2022 | 660 | 0.400 |
Why?
|
| Virus Replication | 6 | 2023 | 304 | 0.390 |
Why?
|
| Antiviral Agents | 2 | 2012 | 311 | 0.390 |
Why?
|
| Antibodies, Viral | 4 | 2022 | 291 | 0.390 |
Why?
|
| Cyclophilins | 1 | 2011 | 12 | 0.380 |
Why?
|
| Viral Load | 6 | 2023 | 219 | 0.380 |
Why?
|
| Blood-Brain Barrier | 2 | 2022 | 81 | 0.370 |
Why?
|
| Viruses | 3 | 2025 | 78 | 0.340 |
Why?
|
| Influenza B virus | 2 | 2021 | 7 | 0.340 |
Why?
|
| Sequence Deletion | 2 | 2009 | 112 | 0.340 |
Why?
|
| Viral Tropism | 2 | 2020 | 50 | 0.330 |
Why?
|
| Coronavirus 229E, Human | 1 | 2009 | 2 | 0.330 |
Why?
|
| Respiratory Tract Infections | 3 | 2024 | 84 | 0.320 |
Why?
|
| Virulence Factors | 1 | 2009 | 80 | 0.310 |
Why?
|
| Nasopharynx | 4 | 2021 | 20 | 0.310 |
Why?
|
| Influenza A virus | 2 | 2021 | 116 | 0.310 |
Why?
|
| Feces | 3 | 2025 | 97 | 0.300 |
Why?
|
| Pediatrics | 2 | 2007 | 240 | 0.290 |
Why?
|
| Cooperative Behavior | 1 | 2009 | 210 | 0.280 |
Why?
|
| Homes for the Aged | 2 | 2008 | 157 | 0.280 |
Why?
|
| Attitude of Health Personnel | 2 | 2008 | 550 | 0.280 |
Why?
|
| Adaptation, Psychological | 1 | 2009 | 259 | 0.280 |
Why?
|
| Poverty | 1 | 2009 | 281 | 0.270 |
Why?
|
| Patient Care Management | 1 | 2006 | 30 | 0.270 |
Why?
|
| Immunocompromised Host | 2 | 2024 | 98 | 0.260 |
Why?
|
| Mothers | 1 | 2009 | 255 | 0.260 |
Why?
|
| Spike Glycoprotein, Coronavirus | 9 | 2022 | 94 | 0.250 |
Why?
|
| Phylogeny | 3 | 2020 | 336 | 0.250 |
Why?
|
| Peptidyl-Dipeptidase A | 3 | 2012 | 42 | 0.250 |
Why?
|
| Female | 19 | 2024 | 30695 | 0.250 |
Why?
|
| Lung | 4 | 2022 | 913 | 0.250 |
Why?
|
| Nursing Homes | 2 | 2008 | 661 | 0.250 |
Why?
|
| Gastroenteritis | 1 | 2025 | 12 | 0.240 |
Why?
|
| Travel | 2 | 2020 | 37 | 0.240 |
Why?
|
| Male | 18 | 2024 | 27727 | 0.240 |
Why?
|
| Diarrhea | 1 | 2025 | 74 | 0.230 |
Why?
|
| Rubella | 1 | 2024 | 1 | 0.230 |
Why?
|
| Mumps | 1 | 2024 | 2 | 0.230 |
Why?
|
| Chickenpox | 1 | 2024 | 3 | 0.230 |
Why?
|
| Measles | 1 | 2024 | 3 | 0.230 |
Why?
|
| Reproducibility of Results | 4 | 2022 | 1561 | 0.230 |
Why?
|
| Vero Cells | 5 | 2021 | 75 | 0.230 |
Why?
|
| Brain | 3 | 2021 | 1487 | 0.230 |
Why?
|
| Lymphogranuloma Venereum | 1 | 2024 | 3 | 0.230 |
Why?
|
| Serologic Tests | 2 | 2021 | 34 | 0.220 |
Why?
|
| Primary Dysautonomias | 1 | 2023 | 7 | 0.220 |
Why?
|
| Mental Health Services | 1 | 2007 | 268 | 0.220 |
Why?
|
| Laboratories | 2 | 2021 | 27 | 0.210 |
Why?
|
| Herpesviridae | 1 | 2023 | 14 | 0.210 |
Why?
|
| Antibodies, Neutralizing | 2 | 2022 | 177 | 0.210 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2023 | 89 | 0.200 |
Why?
|
| Depression | 1 | 2009 | 828 | 0.200 |
Why?
|
| Health Services Accessibility | 1 | 2007 | 521 | 0.200 |
Why?
|
| Viral Vaccines | 1 | 2022 | 47 | 0.190 |
Why?
|
| Middle Aged | 14 | 2024 | 16310 | 0.190 |
Why?
|
| Herpesvirus 4, Human | 1 | 2023 | 178 | 0.190 |
Why?
|
| Physicians | 1 | 2007 | 426 | 0.190 |
Why?
|
| Adult | 11 | 2024 | 15663 | 0.190 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2022 | 42 | 0.190 |
Why?
|
| Microvessels | 1 | 2021 | 17 | 0.190 |
Why?
|
| Prospective Studies | 4 | 2024 | 3065 | 0.190 |
Why?
|
| Gonorrhea | 1 | 2024 | 179 | 0.190 |
Why?
|
| Influenza, Human | 2 | 2021 | 191 | 0.180 |
Why?
|
| Cornea | 1 | 2021 | 17 | 0.180 |
Why?
|
| Primary Health Care | 1 | 2006 | 643 | 0.180 |
Why?
|
| Viremia | 1 | 2021 | 44 | 0.180 |
Why?
|
| Cytarabine | 1 | 2020 | 32 | 0.180 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2021 | 73 | 0.180 |
Why?
|
| BK Virus | 1 | 2021 | 24 | 0.180 |
Why?
|
| Th17 Cells | 1 | 2021 | 57 | 0.180 |
Why?
|
| Contact Tracing | 1 | 2020 | 14 | 0.180 |
Why?
|
| Respiratory Mucosa | 1 | 2020 | 53 | 0.180 |
Why?
|
| Polyomavirus Infections | 1 | 2021 | 46 | 0.180 |
Why?
|
| Italy | 1 | 2020 | 63 | 0.180 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2020 | 39 | 0.180 |
Why?
|
| Multigene Family | 1 | 2020 | 92 | 0.170 |
Why?
|
| Antigens, Viral | 1 | 2021 | 129 | 0.170 |
Why?
|
| Aged | 12 | 2024 | 13412 | 0.170 |
Why?
|
| Gentian Violet | 1 | 2020 | 3 | 0.170 |
Why?
|
| Phenazines | 1 | 2020 | 9 | 0.170 |
Why?
|
| Cell Line | 7 | 2020 | 1968 | 0.170 |
Why?
|
| Hospitals, University | 1 | 2020 | 52 | 0.170 |
Why?
|
| Central Nervous System | 1 | 2022 | 193 | 0.170 |
Why?
|
| Aged, 80 and over | 7 | 2021 | 5128 | 0.160 |
Why?
|
| Mental Disorders | 1 | 2006 | 717 | 0.160 |
Why?
|
| Bacterial Toxins | 1 | 2020 | 60 | 0.160 |
Why?
|
| Tertiary Care Centers | 1 | 2020 | 100 | 0.160 |
Why?
|
| Colistin | 1 | 2019 | 7 | 0.160 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2019 | 10 | 0.160 |
Why?
|
| Enterobacteriaceae | 1 | 2019 | 14 | 0.160 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2021 | 324 | 0.160 |
Why?
|
| Clostridium Infections | 1 | 2020 | 45 | 0.160 |
Why?
|
| Muscle, Skeletal | 1 | 2024 | 674 | 0.160 |
Why?
|
| Host-Pathogen Interactions | 2 | 2011 | 236 | 0.160 |
Why?
|
| Pseudomonas Infections | 1 | 2019 | 51 | 0.160 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 262 | 0.160 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2019 | 22 | 0.160 |
Why?
|
| Immunologic Memory | 1 | 2021 | 281 | 0.150 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 365 | 0.150 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2019 | 83 | 0.150 |
Why?
|
| Acute Kidney Injury | 1 | 2020 | 132 | 0.150 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2019 | 99 | 0.150 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 141 | 0.150 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2020 | 167 | 0.150 |
Why?
|
| Evolution, Molecular | 1 | 2020 | 298 | 0.150 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2020 | 438 | 0.150 |
Why?
|
| Animals | 12 | 2021 | 19601 | 0.150 |
Why?
|
| Sequence Analysis, DNA | 2 | 2009 | 393 | 0.150 |
Why?
|
| Pulmonary Embolism | 1 | 2020 | 170 | 0.150 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 328 | 0.150 |
Why?
|
| Kidney | 1 | 2020 | 416 | 0.140 |
Why?
|
| Health Personnel | 1 | 2021 | 340 | 0.140 |
Why?
|
| Mesocricetus | 2 | 2021 | 93 | 0.130 |
Why?
|
| Molecular Sequence Data | 2 | 2009 | 1949 | 0.130 |
Why?
|
| HIV Infections | 1 | 2022 | 912 | 0.120 |
Why?
|
| Cricetinae | 2 | 2021 | 365 | 0.120 |
Why?
|
| Virus Diseases | 2 | 2024 | 114 | 0.120 |
Why?
|
| Caco-2 Cells | 2 | 2011 | 66 | 0.110 |
Why?
|
| Bacterial Proteins | 1 | 2020 | 732 | 0.110 |
Why?
|
| Young Adult | 5 | 2024 | 4266 | 0.110 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2014 | 93 | 0.110 |
Why?
|
| Limit of Detection | 2 | 2025 | 43 | 0.110 |
Why?
|
| Cross-Sectional Studies | 3 | 2024 | 2373 | 0.110 |
Why?
|
| Automation, Laboratory | 2 | 2024 | 8 | 0.100 |
Why?
|
| DNA, Viral | 2 | 2023 | 223 | 0.100 |
Why?
|
| Receptors, Virus | 1 | 2012 | 67 | 0.090 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2011 | 65 | 0.090 |
Why?
|
| Jurkat Cells | 1 | 2011 | 103 | 0.090 |
Why?
|
| Cyclosporine | 1 | 2011 | 76 | 0.090 |
Why?
|
| Protein Interaction Mapping | 1 | 2011 | 68 | 0.090 |
Why?
|
| Endothelial Cells | 2 | 2023 | 173 | 0.090 |
Why?
|
| Oropharynx | 2 | 2021 | 12 | 0.090 |
Why?
|
| Job Satisfaction | 2 | 2008 | 133 | 0.090 |
Why?
|
| Protease Inhibitors | 1 | 2011 | 104 | 0.090 |
Why?
|
| Vaccination | 2 | 2024 | 333 | 0.090 |
Why?
|
| Professional-Patient Relations | 2 | 2008 | 127 | 0.090 |
Why?
|
| Immunohistochemistry | 2 | 2024 | 846 | 0.090 |
Why?
|
| Mannose-Binding Lectin | 1 | 2010 | 3 | 0.090 |
Why?
|
| Workflow | 2 | 2021 | 63 | 0.090 |
Why?
|
| Rabies virus | 1 | 2010 | 4 | 0.090 |
Why?
|
| Virology | 1 | 2010 | 13 | 0.090 |
Why?
|
| Rabies | 1 | 2010 | 4 | 0.090 |
Why?
|
| Asparagine | 1 | 2010 | 24 | 0.090 |
Why?
|
| Serine Endopeptidases | 1 | 2011 | 83 | 0.090 |
Why?
|
| Ghana | 1 | 2009 | 10 | 0.080 |
Why?
|
| Chromosomes, Artificial, Bacterial | 1 | 2009 | 19 | 0.080 |
Why?
|
| Immunoglobulin G | 2 | 2022 | 445 | 0.080 |
Why?
|
| HEK293 Cells | 1 | 2011 | 586 | 0.080 |
Why?
|
| Viral Matrix Proteins | 1 | 2009 | 47 | 0.080 |
Why?
|
| Virulence | 1 | 2009 | 186 | 0.080 |
Why?
|
| Job Description | 1 | 2008 | 22 | 0.080 |
Why?
|
| Down-Regulation | 1 | 2009 | 305 | 0.080 |
Why?
|
| Adolescent | 4 | 2024 | 5822 | 0.080 |
Why?
|
| Membrane Microdomains | 1 | 2008 | 48 | 0.080 |
Why?
|
| Peptides | 1 | 2012 | 547 | 0.070 |
Why?
|
| Hospitals | 2 | 2022 | 375 | 0.070 |
Why?
|
| Workload | 1 | 2008 | 118 | 0.070 |
Why?
|
| New Hampshire | 1 | 2007 | 42 | 0.070 |
Why?
|
| Cholesterol | 1 | 2008 | 252 | 0.070 |
Why?
|
| Patient Participation | 1 | 2009 | 216 | 0.070 |
Why?
|
| Focus Groups | 1 | 2008 | 288 | 0.070 |
Why?
|
| Practice Management, Medical | 1 | 2006 | 21 | 0.070 |
Why?
|
| Liver | 2 | 2022 | 796 | 0.070 |
Why?
|
| Child | 3 | 2020 | 4173 | 0.070 |
Why?
|
| Inflammation | 2 | 2023 | 1094 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2022 | 2372 | 0.060 |
Why?
|
| Bacterial Infections | 1 | 2007 | 140 | 0.060 |
Why?
|
| Health Services Research | 1 | 2006 | 265 | 0.060 |
Why?
|
| Seroepidemiologic Studies | 1 | 2024 | 48 | 0.060 |
Why?
|
| Serotyping | 1 | 2024 | 50 | 0.060 |
Why?
|
| Bacteria | 1 | 2007 | 279 | 0.060 |
Why?
|
| Sex Factors | 1 | 2006 | 935 | 0.050 |
Why?
|
| Chlamydia trachomatis | 1 | 2024 | 56 | 0.050 |
Why?
|
| Abscess | 1 | 2024 | 76 | 0.050 |
Why?
|
| Virus Inactivation | 1 | 2023 | 2 | 0.050 |
Why?
|
| Vagus Nerve | 1 | 2023 | 20 | 0.050 |
Why?
|
| Genetic Vectors | 1 | 2009 | 807 | 0.050 |
Why?
|
| Medicaid | 1 | 2006 | 334 | 0.050 |
Why?
|
| Patients' Rooms | 1 | 2022 | 7 | 0.050 |
Why?
|
| Disinfection | 1 | 2022 | 20 | 0.050 |
Why?
|
| Age Factors | 1 | 2006 | 1504 | 0.050 |
Why?
|
| Mouthwashes | 1 | 2022 | 5 | 0.050 |
Why?
|
| Ultraviolet Rays | 1 | 2023 | 127 | 0.050 |
Why?
|
| Imines | 1 | 2022 | 4 | 0.050 |
Why?
|
| Fibroblasts | 1 | 2024 | 377 | 0.050 |
Why?
|
| Quality of Health Care | 1 | 2006 | 510 | 0.050 |
Why?
|
| Ethylene Glycols | 1 | 2022 | 10 | 0.050 |
Why?
|
| Benzamidines | 1 | 2022 | 1 | 0.050 |
Why?
|
| Tropism | 1 | 2022 | 16 | 0.050 |
Why?
|
| Neutralization Tests | 1 | 2022 | 117 | 0.050 |
Why?
|
| Trust | 1 | 2022 | 67 | 0.050 |
Why?
|
| Guanidines | 1 | 2022 | 14 | 0.050 |
Why?
|
| Lactation | 1 | 2022 | 66 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2022 | 146 | 0.050 |
Why?
|
| Saliva | 1 | 2022 | 99 | 0.050 |
Why?
|
| Immunoglobulin A | 1 | 2022 | 94 | 0.050 |
Why?
|
| Pyridines | 1 | 2022 | 98 | 0.050 |
Why?
|
| DNA Primers | 1 | 2022 | 289 | 0.050 |
Why?
|
| Prevalence | 2 | 2020 | 1252 | 0.050 |
Why?
|
| Corneal Transplantation | 1 | 2021 | 1 | 0.050 |
Why?
|
| Neisseria gonorrhoeae | 1 | 2024 | 230 | 0.050 |
Why?
|
| Virus Shedding | 1 | 2021 | 17 | 0.050 |
Why?
|
| Optic Nerve | 1 | 2021 | 25 | 0.050 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2006 | 687 | 0.050 |
Why?
|
| Immunocompetence | 1 | 2021 | 20 | 0.050 |
Why?
|
| Antibodies | 1 | 2022 | 179 | 0.050 |
Why?
|
| Milk, Human | 1 | 2022 | 87 | 0.050 |
Why?
|
| Leukemia, B-Cell | 1 | 2020 | 6 | 0.050 |
Why?
|
| Azacitidine | 1 | 2020 | 13 | 0.050 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2021 | 101 | 0.050 |
Why?
|
| Clone Cells | 1 | 2021 | 106 | 0.040 |
Why?
|
| Neuropathology | 1 | 2020 | 3 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2022 | 5283 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2021 | 63 | 0.040 |
Why?
|
| Point-of-Care Testing | 1 | 2021 | 43 | 0.040 |
Why?
|
| Specimen Handling | 1 | 2021 | 61 | 0.040 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2020 | 34 | 0.040 |
Why?
|
| Cadaver | 1 | 2020 | 110 | 0.040 |
Why?
|
| Infant | 2 | 2020 | 1486 | 0.040 |
Why?
|
| Myeloid Cells | 1 | 2021 | 89 | 0.040 |
Why?
|
| Retina | 1 | 2021 | 115 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 2020 | 76 | 0.040 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2022 | 139 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2022 | 219 | 0.040 |
Why?
|
| Immunity | 1 | 2021 | 100 | 0.040 |
Why?
|
| Pharynx | 1 | 2020 | 21 | 0.040 |
Why?
|
| Proteomics | 1 | 2022 | 263 | 0.040 |
Why?
|
| Breast Feeding | 1 | 2022 | 143 | 0.040 |
Why?
|
| Pneumonia, Bacterial | 1 | 2021 | 88 | 0.040 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2020 | 27 | 0.040 |
Why?
|
| Child, Preschool | 2 | 2020 | 1782 | 0.040 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2020 | 52 | 0.040 |
Why?
|
| Glycosylation | 2 | 2010 | 129 | 0.040 |
Why?
|
| Linear Models | 1 | 2020 | 402 | 0.040 |
Why?
|
| Influenza in Birds | 1 | 2019 | 3 | 0.040 |
Why?
|
| Birds | 1 | 2019 | 8 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2007 | 2511 | 0.040 |
Why?
|
| Graft Rejection | 1 | 2021 | 289 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 445 | 0.040 |
Why?
|
| Cause of Death | 1 | 2020 | 210 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2020 | 495 | 0.040 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2019 | 34 | 0.040 |
Why?
|
| DNA | 1 | 2023 | 806 | 0.040 |
Why?
|
| Macrophages | 1 | 2024 | 1000 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2019 | 189 | 0.040 |
Why?
|
| Genomics | 1 | 2021 | 318 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2022 | 1283 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2021 | 1204 | 0.040 |
Why?
|
| Heart | 1 | 2020 | 274 | 0.040 |
Why?
|
| Case-Control Studies | 1 | 2021 | 1051 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2022 | 837 | 0.040 |
Why?
|
| Transcriptome | 1 | 2020 | 338 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 407 | 0.040 |
Why?
|
| Critical Illness | 1 | 2021 | 325 | 0.030 |
Why?
|
| Critical Care | 1 | 2021 | 397 | 0.030 |
Why?
|
| Models, Biological | 1 | 2022 | 1140 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2021 | 1985 | 0.030 |
Why?
|
| Protein Binding | 2 | 2012 | 1554 | 0.030 |
Why?
|
| Prognosis | 1 | 2020 | 1599 | 0.030 |
Why?
|
| Mass Screening | 1 | 2020 | 645 | 0.030 |
Why?
|
| Archaeal Proteins | 1 | 2014 | 6 | 0.030 |
Why?
|
| Exoribonucleases | 1 | 2014 | 25 | 0.030 |
Why?
|
| Protein Interaction Maps | 1 | 2014 | 33 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2021 | 3220 | 0.030 |
Why?
|
| Methyltransferases | 1 | 2014 | 50 | 0.030 |
Why?
|
| Mutagenesis | 1 | 2014 | 129 | 0.030 |
Why?
|
| Crystallography, X-Ray | 1 | 2014 | 424 | 0.030 |
Why?
|
| Hospitalization | 1 | 2020 | 1290 | 0.030 |
Why?
|
| Time Factors | 1 | 2020 | 3614 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 1525 | 0.030 |
Why?
|
| Surface Plasmon Resonance | 1 | 2012 | 33 | 0.020 |
Why?
|
| Immunity, Humoral | 1 | 2011 | 37 | 0.020 |
Why?
|
| Virus Cultivation | 1 | 2010 | 17 | 0.020 |
Why?
|
| Europe | 1 | 2010 | 184 | 0.020 |
Why?
|
| China | 1 | 2010 | 134 | 0.020 |
Why?
|
| Cell Adhesion Molecules | 1 | 2010 | 85 | 0.020 |
Why?
|
| Lectins, C-Type | 1 | 2010 | 77 | 0.020 |
Why?
|
| Amino Acid Motifs | 1 | 2010 | 150 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2021 | 6071 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 583 | 0.020 |
Why?
|
| Golgi Apparatus | 1 | 2009 | 63 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2009 | 248 | 0.020 |
Why?
|
| beta-Cyclodextrins | 1 | 2008 | 20 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2009 | 234 | 0.020 |
Why?
|
| Consumer Behavior | 1 | 2008 | 35 | 0.020 |
Why?
|
| Mice | 1 | 2021 | 10251 | 0.020 |
Why?
|
| Base Sequence | 1 | 2010 | 1300 | 0.020 |
Why?
|
| Transfection | 1 | 2009 | 675 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 2010 | 428 | 0.020 |
Why?
|
| Aircraft | 1 | 2007 | 18 | 0.020 |
Why?
|
| Age Distribution | 1 | 2007 | 249 | 0.020 |
Why?
|
| Quality of Life | 1 | 2008 | 1137 | 0.010 |
Why?
|